Navigation Links
Upsher-Smith To Present New Research On USL255 (Extended-Release Topiramate) At 2013 American Epilepsy Society Annual Meeting
Date:11/18/2013

earch/mode/display/st/usl255/sy/2013/sb/All/id/1729022">Impact of Delayed-Dose Administration of USL255, an Extended-Release Topiramate Formulation  
Poster 2.157; Sunday, December 8, 2013; 8 a.m. – 5 p.m. EST;  
Authors Present 12 p.m. – 2 p.m.

Abstracts of the poster presentations can be found online at www.aesnet.org.  To schedule an interview with an investigator, please contact Elizabeth Likly at elikly@klcpr.com.  

About Upsher-Smith's Phase 3 (PREVAIL) Clinical Trial

The PREVAIL trial was a randomized, multicenter, double-blind, placebo-controlled, parallel-group study designed to evaluate the efficacy and safety of USL255 as adjunctive therapy in patients with refractory POS. 

PREVAIL was conducted under a Special Protocol Assessment (SPA) agreement with the FDA.  More information about the trial is available at www.clinicaltrials.gov (NCT01142193).

An open-label extension study to evaluate the safety of USL255 as adjunctive therapy in patients with refractory POS who had participated in PREVAIL is ongoing.  The open-label extension study can be found by searching NCT01191086 on www.clinicaltrials.gov.

Upsher-Smith's Epilepsy Pipeline

Upsher-Smith's clinical development pipeline includes three investigational drugs that are being studied for the management of seizure disorders.  USL255 is an investigational once-daily, extended-release topiramate for the management
'/>"/>

SOURCE Upsher-Smith Laboratories, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Upsher-Smith Research Shows Unique Pharmacokinetic Profile of USL255 Extended Release Topiramate
2. Dave Zitnak Of Upsher-Smith Laboratories Named Branded Representative Of The Year By McKesson Corporation
3. Upsher-Smith Is Honored with Prestigious Industry Award for Excellence and Innovation
4. Upsher-Smith Teams Up With Epilepsy Foundation of Minnesota for 2012 Stroll for Epilepsy
5. Tina Fehr, Senior Product Manager For AmLactin, Upsher-Smith Laboratories Named PM360 Trailblazer Winner For Womens Health Brand Manager
6. Doug Zitnak of Upsher-Smith Laboratories Named Small Brand Manufacturer Representative of the Year By Cardinal Health
7. Emerging Data From Upsher-Smiths CNS Portfolio Highlighted At 2013 American Academy Of Neurology Meeting
8. Upsher-Smith Presents Data Supporting Favorable Tolerability And Consistent Pharmacokinetic Profile Of Once-Daily USL255 (Extended-Release Topiramate)
9. Upsher-Smith Introduces Newly Redesigned Corporate Website
10. Upsher-Smith Successfully Completes Phase III Study Of USL255 (Extended-Release Topiramate) For Adjunctive Treatment Of Epilepsy In Patients With Refractory Partial-Onset Seizures
11. Upsher-Smith Is Honored With Prestigious Industry Award For Leadership And Innovation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... Calif. , May 1, 2015 The ... its 2015 health literacy award winners. The IHA Health ... that make an impact on the practice of educating ... health literacy. IHA gives awards in three categories: innovative ... bestowed its Health Literacy Hero award. In ...
(Date:5/1/2015)... May 1, 2015  Misonix, Inc. (NASDAQ: ... designs, manufactures and markets innovative therapeutic ultrasonic products ... cosmetic surgery, laparoscopic surgery and other surgical applications, ... for the third quarter fiscal year 2015 on ... a conference call that same day, Thursday, May ...
(Date:4/30/2015)... Abaxis, Inc. (NasdaqGS: ABAX ), a medical products ... results for the fourth quarter and fiscal year ended ... 2015 overview: , Revenues from continuing operations of ... last year,s comparable quarter, and $202.6 million for fiscal ... $0.50 for the fourth quarter, up 194% over last ...
Breaking Medicine Technology:Institute for Healthcare Advancement Announces 2015 Award Winners 2Misonix, Inc. To Report Third Quarter Fiscal Year 2015 Financial Results On Thursday, May 7, 2015 2Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 2Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 3Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 4Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 5Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 6Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 7Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 8Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 9Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 10Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 11Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 12Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 13Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 14Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 15Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 16Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 17Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 18Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 19Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 20Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 21Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 22Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 23Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 24
... Viveve, Inc. , a development stage women,s health company, ... (Conformite Europeenne) mark for the use of its Viveve ... vaginal introitus (opening), after childbirth, to improve female sexual ... "The CE mark is a key milestone in our ...
... SAN FRANCISCO, Jan. 6, 2011 Rigel Pharmaceuticals, Inc. (Nasdaq: ... the company,s chairman and chief executive officer, is scheduled to ... in San Francisco, CA on Thursday, January 13th at 11:30 ... To access the live audio webcast or the subsequent archived ...
Cached Medicine Technology:Viveve Obtains CE Mark for Gynecologic Treatment of Vaginal Laxity 2
(Date:5/3/2015)... “ BolehVPN ” was featured on NewsWatch as part of ... technology products available to consumers. Scott Steinberg, a technology expert ... with viewers how to protect their private information. , A ... and even more so online. It helps everyone stay connected ... world. In terms of work, the internet makes things more ...
(Date:5/3/2015)... Burnsville MN (PRWEB) May 03, 2015 ... in workplace safety solutions, announces its appearance at the ... Health Conference. Products that HealthPostures will exhibit at the ... Largest of the sit stand solutions is the 6100 ... push button height control, an adjustable keyboard tray, extended ...
(Date:5/2/2015)... May 02, 2015 ProText Kinetic 2 is ... in Final Cut Pro X. ProText Kinetic 2 features ... Final Cut Pro X . Easily create interactive ... Pixel Film Studios' ProText Kinetic 2. , Using ProText Kinetic ... staggering two ProText Kinetic presets in the FCPX timeline. ...
(Date:5/2/2015)... May 02, 2015 Kare Visits LLC. launched ... for busy caregivers. Kare Visits offers relief for caregivers ... living facilities. According to the Caregiver Action Network, ... average of 20 hours a week caring for an elderly ... cost to hire a nurse, a caregiver is now empowered ...
(Date:5/1/2015)... and Caicos Islands, BWI (PRWEB) May 02, 2015 ... new website! It is http://www.thevenetiangracebay.com , and ... and it incorporates the stunning white and attractive turquoise ... a study of Google, sixty seven percent of leisure ... The study showed that smartphones were used in the ...
Breaking Medicine News(10 mins):Health News:A Method to Keep Private Information Secure was Featured on NewsWatch Television 2Health News:HealthPostures to Appear at the Minnesota Safety and Health Conference 2Health News:HealthPostures to Appear at the Minnesota Safety and Health Conference 3Health News:Pixel Film Studios Announced the Release of Protext Kinetic 2 for FPCX. 2Health News:Chicagoan Seeks to Transform Industry by Launching an Innovative Elderly Care Solution 2Health News:Turks and Caicos Resort, The Venetian on Grace Bay, Launches New Web Presence 2
... Sept. 5 The Health Resources,and Services Administration ... and improve medical services at the nation,s health ... expansion of the,health center network, whose services now ... ever before," HRSA,Administrator Elizabeth M. Duke said. "In ...
... Arthrosurface, Inc.,( http://www.arthrosurface.com ), the developer of ... approval from the U.S.,FDA to begin its pivotal ... The FDA stated that "there are no outstanding ... initiation., Arthrosurface has been evaluating the safety ...
... Sept. 5 U.S. citizens can donate,money to ... Hurricane,Gustav, which is the worst storm to hit ... "Donations will be used for basic supplies that ... Wachtenheim, Director of the Cuban,Development Initiative at the ...
... say patients taking meds on Web site shouldn,t overreact or ... The U.S. Food and Drug Administration has started listing on ... the agency said Friday. , "If a drug appears ... to determine whether there is a safety problem that requires ...
... to physicians by pharmaceutical companies could actually be costing ... a study done by researchers at Wake Forest University ... looked at the prescribing habits of more than 70 ... months immediately before and after the closing of their ...
... 3 studies focus on brain and pancreatic tumors , , ... involving genetic mutations of two deadly cancers -- the ... to new treatments and even cures, researchers say. ... to date of any tumor type and provide a ...
Cached Medicine News:Health News:HRSA Announces $39 Million in Grants to Expand, Improve Health Center Services 2Health News:Arthrosurface HemiCAP(R) Focal Knee Resurfacing Implant Receives FDA Approval to Move into Final Investigational Stage 2Health News:Cuban Disaster Relief Donations Sought in the Wake of Hurricane Gustav 2Health News:FDA to List Drugs Under Review for Safety Issues 2Health News:Free drug samples may end up costing uninsured more 2Health News:Free drug samples may end up costing uninsured more 3Health News:Genetic Mutations Linked to Deadly Cancers 2Health News:Genetic Mutations Linked to Deadly Cancers 3Health News:Genetic Mutations Linked to Deadly Cancers 4
For the quantitative determination of Albumin in serum. Endpoint procedure with Amax at 630 nm. Linearity: to 6 g/dl. Liquid ready-to-use reagent....
AST (SGOT) R1 + R2. Automated analyzer test kits....
For the quantitative colorimetric determination of AST (SGOT) in serum....
Intended for the quantitative determination of aspartate aminotransferase activity in serum or plasma. Reaction: Kinetic. Wavelength: 340 nm. Linearity: 440 U/L at 30C. Single vial, dry powder reagen...
Medicine Products: